Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, Keytruda (Merck & Co.) plus Inlyta (Pfizer), Bavencio (Merck KGaA / Pfizer) plus Inlyta, are revolutionizing the treatment of advanced disease. Angiogenesis inhibitors such as Sutent (Pfizer), Votrient (Novartis), and Cabometyx (Exelixis / Ipsen) remain a key feature of first-line treatment. The entry and increased uptake of Cabometyx and Opdivo in this setting are beginning to shift Inlyta and Lenvima / Kisplyx (Eisai) plus Afinitor (Novartis) to later lines. Furthermore, following Sutent’s approval for high-risk early-stage (stage I-III) patients, multiple immune checkpoint inhibitors are anticipated to transition to the early-stage setting. The renal cell carcinoma therapy market remains highly competitive and dynamic, but the developer of an efficacious therapy can expect to reap high commercial rewards.

Questions Answered:

  • How are the early-stage and advanced or metastatic drug-treatable renal cell carcinoma populations defined, and how will drug-treatment rates evolve over the forecast period?
  • What is the current treatment landscape for renal cell carcinoma, and what are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • What is the outlook for key combination regimens in renal cell carcinoma? How will these combination regimens be differentiated, and which look the most promising?
  • Which emerging therapies do we forecast to enter the renal cell carcinoma market? What uptake and sales are these therapies anticipated to secure?

Contents Highlights

Geographies: United States, EU5, Japan

Primary Research: 19 country-specific interviews with thought-leading medical oncologists and urologists. Supported by survey data collected for this and other DRG research.

Epidemiology: Diagnosed and recurrent incidence of renal cell carcinoma by country, segmented by drug-treatable and -treated early-stage and locally advanced or metastatic disease and line of therapy.

Forecast: 10-year, annualized, drug-level sales and patient share of key renal cell carcinoma therapies through 2029, segmented by brands/generics and epidemiological subpopulations.

Emerging Therapies: Phase III/PR: 7 drugs; Phase II: 9 drugs; coverage of select preclinical and Phase I products.

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Renal Cell Carcinoma - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q2 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
      • Q3 2020
        • July 2020
      • Q2 2020
        • May 2020
      • Q1 2020
        • March 2020
      • Q4 2019
        • December 2019
    • Key Findings
      • Market Outlook
        • Key Findings
          • Market Share of Drug Classes for Renal Cell Carcinoma: 2019
          • Market Share of Drug Classes for Renal Cell Carcinoma: 2029
          • Drug-Treatable Population Share and Major-Market Sales Share in Renal Cell Carcinoma: 2019
          • Drug-Treatable Population Share and Major-Market Sales Share in Renal Cell Carcinoma: 2029
          • Population Positioning of Current Therapies in Renal Cell Carcinoma
          • Population Positioning of Emerging Therapies in Renal Cell Carcinoma
          • Renal Cell Carcinoma SWOT Analysis
        • COVID-19: Areas of Potential Forecast Impact
          • Expert Insight: COVID-19 Impact
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Renal Cell Carcinoma?
          • What Factors Are Constraining the Market for Renal Cell Carcinoma?
          • Major-Market Sales for Renal Cell Carcinoma by Drug-Treatable Population, 2019-2029
          • Major-Market Sales of Immune Oncology Therapies for Renal Cell Carcinoma, 2019-2029
          • Major-Market Sales of Angiogenesis Inhibitors for Renal Cell Carcinoma, 2019-2029
        • Segment-Specific Trends
          • Patient-Share Dynamics of Therapies for Early-Stage (Stage I-III) Renal Cell Carcinoma, United States, 2019-2029
          • Patient-Share Dynamics of Key Therapies in First-Line Advanced or Metastatic Renal Cell Carcinoma, United States, 2019-2029
          • Patient-Share Dynamics of Key Therapies in First-Line Advanced or Metastatic Renal Cell Carcinoma, Japan, 2019-2029
          • Patient-Share Dynamics of Key Therapies in Second-Line Advanced or Metastatic Renal Cell Carcinoma, United States, 2019-2029
          • Patient-Share Dynamics of Key Therapies in Second-Line Advanced or Metastatic Renal Cell Carcinoma, Japan, 2019-2029
          • Patient-Share Dynamics of Key Therapies in Third-Line Advanced or Metastatic Renal Cell Carcinoma, United States, 2019-2029
          • Patient-Share Dynamics of Key Therapies in Third-Line Advanced or Metastatic Renal Cell Carcinoma, Japan, 2019-2029
          • Patient-Share Dynamics of Key Therapies in Fourth-Line Advanced or Metastatic Renal Cell Carcinoma, United States, 2019-2029
          • Patient-Share Dynamics of Key Therapies in Fourth-Line Advanced or Metastatic Renal Cell Carcinoma, Japan, 2019-2029
      • Forecast
        • Market Forecast Assumptions
        • Market Forecast Dashboard
      • Etiology and Pathophysiology
        • Disease Overview
          • Progression of Renal Cell Carcinoma
          • Anatomy and Histology of Renal Cell Carcinoma
          • Prognostic Models for Renal Cell Carcinoma
          • International Metastatic RCC Database Consortium Risk Assessment System for Stage IV Renal Cell Carcinoma
          • UCLA Integrated Staging System for Renal Cell Carcinoma
          • Classification of Renal Cell Carcinoma
          • Staging of Renal Cell Carcinoma
          • TNM Staging System for Renal Cell Carcinoma
          • Definitions of the TNM Staging System for Renal Cell Carcinoma
          • Key Pathways and Drug Targets for Renal Cell Carcinoma
      • Epidemiology
        • Key Findings
          • Key Updates
        • Epidemiology Populations
          • Disease Definition
          • Methods
          • Sources Used for Diagnosed Incidence of Renal Cell Carcinoma
          • Diagnosed Incident Cases of Renal Cell Carcinoma: 2019-2029
          • Disease Definition
          • Methods
          • Sources Used for Stage Distribution of Renal Cell Carcinoma
          • Diagnosed Incident Cases of Renal Cell Carcinoma by Stage Distribution: 2019-2029
          • Disease Definition
          • Methods
          • Sources Used for Recurrent Incidence of Renal Cell Carcinoma
          • Recurrent Incident Cases of Renal Cell Carcinoma: 2019-2029
          • Renal Cell Carcinoma Patient Flow
          • Drug-Treatable Populations of Renal Cell Carcinoma in the Major Pharmaceutical Markets, 2019-2029
          • Drug-Treated Cases of Renal Cell Carcinoma: 2019-2029
      • Current Treatment
        • Key Findings
          • Treatment Goals
            • Key Endpoints Used in Clinical Trials for Renal Cell Carcinoma
          • Key Current Therapies
            • Overview
            • Mechanism of Action of Key Current Drug Classes Used for Renal Cell Carcinoma
            • Current Treatments Used for Renal Cell Carcinoma
            • Market Events Influencing the Use of Key Current Therapies in Renal Cell Carcinoma
            • Key Results from Select Clinical Trials Investigating Opdivo for the Treatment of Renal Cell Carcinoma
            • Ongoing Clinical Development of Opdivo
            • Key Ongoing Clinical Trials of Opdivo in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Opdivo
            • Key Results from Select Clinical Trials Investigating Opdivo and Yervoy Combination Therapy for the Treatment of Renal Cell Carcinoma
            • Ongoing Clinical Development of Opdivo and Yervoy Combination Therapy
            • Key Ongoing Clinical Trials of Opdivo and Yervoy Combination Therapy in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Opdivo and Yervoy Combination Therapy
            • Key Results from Select Clinical Trials Investigating Keytruda for the Treatment of Renal Cell Carcinoma
            • Ongoing Clinical Development of Keytruda
            • Key Ongoing Clinical Trials of Keytruda in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Keytruda
            • Key Results from Select Clinical Trials Investigating Bavencio for the Treatment of Renal Cell Carcinoma
            • Ongoing Clinical Development of Bavencio
            • Key Ongoing Clinical Trials of Bavencio in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Bavencio
            • Key Results from Select Clinical Trials Investigating Sutent for the Treatment of Renal Cell Carcinoma
            • Expert Insight: Sutent
            • Key Results from Select Clinical Trials Investigating Votrient for the Treatment of Renal Cell Carcinoma
            • Expert Insight: Votrient
            • Advantages and Disadvantages of Nexavar
            • Expert Insight: Nexavar
            • Key Results from Select Clinical Trials Investigating Inlyta for the Treatment of Renal Cell Carcinoma
            • Expert Insight: Inlyta
            • Advantages and Disadvantages of Avastin
            • Ongoing Clinical Development of Avastin
            • Expert Insight: Avastin
            • Key Results from Select Clinical Trials Investigating Cabometyx for the Treatment of Renal Cell Carcinoma
            • Ongoing Clinical Development of Cabometyx
            • Key Ongoing Clinical Trials of Cabometyx in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Cabometyx
            • Advantages and Disadvantages of Lenvima / Kisplyx
            • Key Results from Select Clinical Trials Investigating Lenvima / Kisplyx for the Treatment of Renal Cell Carcinoma
            • Ongoing Clinical Development of Lenvima / Kisplyx
            • Key Ongoing Clinical Trials of Lenvima / Kisplyx in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Lenvima / Kisplyx
            • Key Results from Select Clinical Trials Investigating Fotivda for the Treatment of Renal Cell Carcinoma
            • Ongoing Clinical Development of Fotivda
            • Expert Insight: Fotivda
            • Advantages and Disadvantages of Torisel
            • Expert Insight: Torisel
            • Advantages and Disadvantages of Afinitor
            • Ongoing Clinical Development of Afinitor
            • Key Ongoing Clinical Trials of Afinitor in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Afinitor
          • Medical Practice
            • Impact of COVID-19 on Medical Practice
            • Early-Stage Renal Cell Carcinoma: Stages I-III
            • First-Line Advanced or Metastatic Renal Cell Carcinoma: Stage IV
            • Second-Line Advanced or Metastatic Renal Cell Carcinoma
            • Third- and Fourth-Line Advanced or Metastatic Renal Cell Carcinoma
            • Country-Specific Renal Cell Carcinoma Treatment Guidelines
            • Patient Characteristics Influencing Drug Selection in Renal Cell Carcinoma
            • Treatment Decision Tree for Renal Cell Carcinoma: United States
            • Treatment Decision Tree for Renal Cell Carcinoma: EU5
            • Treatment Decision Tree for Renal Cell Carcinoma: Japan
        • Unmet Need Overview
          • Current and Future Attainment of Unmet Needs in Renal Cell Carcinoma
          • Top Unmet Needs in Renal Cell Carcinoma: Current and Future Attainment
          • Expert Insight: Unmet Need in Renal Cell Carcinoma
        • Emerging Therapies
          • Key Findings
            • Pipeline Trends in Renal Cell Carcinoma
          • Key Emerging Therapies
            • Key Therapies in Development for Renal Cell Carcinoma
            • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Renal Cell Carcinoma
            • Key Results from Select Clinical Trials Investigating Tecentriq for the Treatment of Renal Cell Carcinoma
            • Analysis of Clinical Development Program for Tecentriq
            • Key Ongoing Clinical Trials of Tecentriq in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Tecentriq
            • Expectations for Market Authorization and Sales Opportunity of Tecentriq in Renal Cell Carcinoma
            • Key Results from Select Clinical Trials Investigating Imfinzi for the Treatment of Renal Cell Carcinoma
            • Analysis of the Clinical Development Program for Imfinzi
            • Key Ongoing Clinical Trials of Imfinzi in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Imfinzi
            • Expectations for Market Authorization and Sales Opportunity of Imfinzi in Renal Cell Carcinoma
            • Key Results from Select Clinical Trials Investigating Tremelimumab for the Treatment of Renal Cell Carcinoma
            • Analysis of Clinical Development Program for Tremelimumab
            • Expert Insight: Tremelimumab
            • Expectations for Market Authorization and Sales Opportunity of Tremelimumab in Renal Cell Carcinoma
            • Key Results from Select Clinical Trials Investigating Savolitinib for the Treatment of Renal Cell Carcinoma
            • Analysis of Clinical Development Program for Savolitinib
            • Key Ongoing Clinical Trials of Savolitinib in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Savolitinib
            • Expectations for Market Authorization and Sales Opportunity of Savolitinib in Renal Cell Carcinoma
            • Key Results from Select Clinical Trials Investigating Dovitinib for the Treatment of Renal Cell Carcinoma
            • Analysis of Clinical Development Program for Dovitinib
            • Expert Insight: Dovitinib
            • Expectations for Market Authorization and Sales Opportunity of Dovitinib in Renal Cell Carcinoma
            • Key Results from Select Clinical Trials Investigating Bempegaldesleukin for the Treatment of Renal Cell Carcinoma
            • Analysis of the Clinical Development Program for Bempegaldesleukin
            • Key Ongoing Clinical Trials of Bempegaldesleukin in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Bempegaldesleukin
            • Expectations for Market Authorization and Sales Opportunity of Bempegaldesleukin in Renal Cell Carcinoma
            • Key Results from Select Clinical Trials Investigating Abexinostat for the Treatment of Renal Cell Carcinoma
            • Analysis of Clinical Development Program for Abexinostat
            • Key Ongoing Clinical Trials of Abexinostat in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Abexinostat
            • Expectations for Market Authorization and Sales Opportunity of Abexinostat in Renal Cell Carcinoma
            • Key Results from Select Clinical Trials Investigating Belzutifan for the Treatment of Renal Cell Carcinoma
            • Analysis of Clinical Development Program for Belzutifan
            • Key Ongoing Clinical Trials of Belzutifan in the Treatment of Renal Cell Carcinoma
            • Expert Insight: Belzutifan
            • Expectations for Market Authorization and Sales Opportunity of Belzutifan in Renal Cell Carcinoma
          • Early-Phase Pipeline Analysis
          • Access and Reimbursement Overview
            • Region-Specific Reimbursement Practices
              • Key Market Considerations in Renal Cell Carcinoma: United States
              • General Reimbursement Environment: United States
              • Key Market Access Considerations in Renal Cell Carcinoma: EU5
              • General Reimbursement Environment: EU5
              • Key Market Access Considerations in Renal Cell Carcinoma: Japan
              • General Reimbursement Environment: Japan
          • Appendix
            • Key Abbreviations Related to Renal Cell Carcinoma
            • Brands, Marketers, and Generic Availability of Key Therapies for Renal Cell Carcinoma, by Market
            • Renal Cell Carcinoma Bibliography

        Author(s): Priyanka Mehra, B.Tech.; Mudasir Khan, M.P.H.; Sorcha Cassidy, M.Res., Ph.D.

        Priyanka Mehra, B.Tech., is an analyst on the Oncology team at Clarivate. She has more than five years of experience working in pharmaceutical research and analytics, involving the management and execution of various strategic analysis projects for multiple oncology indications, secondary and primary research, and competitive intelligence. Previously, she worked as an associate consultant with Prescient Healthcare Group, where she was involved with biosimilar projects for global pharmaceutical clients and designed brand and commercial strategies in a variety of therapy areas, including oncology, immunology, and inflammatory disease. Prior to Prescient, she was a senior analyst at Smart Analyst, where she worked on indication prioritization and clinical landscapes for major oncology indications, including non-small-cell lung cancer, colorectal cancer, and melanoma. Ms. Mehra obtained her bachelor’s degree in biotechnology from Amity University in India.

        Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai.

        Sorcha Cassidy, M.Res., Ph.D., is an associate director on the Oncology team at Clarivate. She manages a team of analysts who produce syndicated primary and secondary market research reports and custom analysis on a wide range of oncology indications. Dr. Cassidy also provides client support for all oncology products and has expertise in hematologic malignancies and CAR T-cell therapies. She has published oncology market assessment articles in Nature Reviews Drug Discovery. Previously, Dr. Cassidy was a market research manager at Janssen UK. She obtained her M.Res. and Ph.D. in immunology from Imperial College London, where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIRs]) on natural killer cells in various diseases.


        Related Reports

        Renal Cell Carcinoma | Disease Landscape and Forecast | G7 | DLSFON0009-2020

        Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, K...

        View Details

        Renal Cell Carcinoma - Epidemiology - Emerging Markets

        DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of...

        View Details

        Renal Cell Carcinoma - Epidemiology - Epidemiology Dashboard

        DRG Epidemiology’s coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence...

        View Details

        Renal Cell Carcinoma - Epidemiology - Extrapolated Worldwide Coverage

        DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key renal cell carcinoma patient populatio...

        View Details